NASDAQ:SELB

Selecta Biosciences News Headlines

$3.87
-0.06 (-1.53 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.76
Now: $3.87
$3.95
50-Day Range
$3.70
MA: $4.22
$4.68
52-Week Range
$1.47
Now: $3.87
$5.70
Volume918,600 shs
Average Volume1.73 million shs
Market Capitalization$434.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18

Headlines

Selecta Biosciences (NASDAQ SELB) News Headlines Today

SourceHeadline
Selecta Biosciences to Participate at the 20th Annual Needham Healthcare ConferenceSelecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference
finance.yahoo.com - April 5 at 9:38 AM
Selecta Biosciences, Inc. (NASDAQ:SELB) Expected to Post Quarterly Sales of $5.88 MillionSelecta Biosciences, Inc. (NASDAQ:SELB) Expected to Post Quarterly Sales of $5.88 Million
americanbankingnews.com - April 5 at 1:58 AM
 Brokerages Anticipate Selecta Biosciences, Inc. (NASDAQ:SELB) Will Post Earnings of -$0.11 Per Share Brokerages Anticipate Selecta Biosciences, Inc. (NASDAQ:SELB) Will Post Earnings of -$0.11 Per Share
americanbankingnews.com - April 3 at 2:14 PM
Selecta Biosciences (NASDAQ:SELB) Trading Down 3.5%Selecta Biosciences (NASDAQ:SELB) Trading Down 3.5%
americanbankingnews.com - April 1 at 11:36 AM
Selecta Biosciences, Inc. (NASDAQ:SELB) Director Buys $41,000.00 in StockSelecta Biosciences, Inc. (NASDAQ:SELB) Director Buys $41,000.00 in Stock
americanbankingnews.com - March 30 at 8:24 PM
Selecta Biosciences, Inc. (NASDAQ:SELB) Given Consensus Rating of "Buy" by AnalystsSelecta Biosciences, Inc. (NASDAQ:SELB) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - March 27 at 3:08 AM
Selecta Biosciences, Inc. (NASDAQ:SELB) Just Reported And Analysts Have Been Lifting Their Price TargetsSelecta Biosciences, Inc. (NASDAQ:SELB) Just Reported And Analysts Have Been Lifting Their Price Targets
finance.yahoo.com - March 13 at 10:05 AM
Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue EstimatesSelecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 11 at 3:09 PM
Selecta Biosciences, Inc. (SELB) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseSelecta Biosciences, Inc. (SELB) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
finance.yahoo.com - March 4 at 5:15 PM
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational HighlightsSelecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
finance.yahoo.com - March 4 at 12:14 PM
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences ConferenceSelecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 1 at 9:15 AM
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus VariantsThe Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
msn.com - February 25 at 8:50 AM
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene TherapySelecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
finance.yahoo.com - February 24 at 5:45 PM
A Look At Selecta Biosciences (NASDAQ:SELB) Share Price ReturnsA Look At Selecta Biosciences' (NASDAQ:SELB) Share Price Returns
finance.yahoo.com - February 22 at 11:49 AM
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR(TM) in Gene TherapySelecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR(TM) in Gene Therapy
theglobeandmail.com - February 17 at 1:06 PM
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene TherapySelecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
finance.yahoo.com - February 17 at 8:05 AM
Selecta Biosciences to Present at the SVB Leerink 10th Annual Global Healthcare ConferenceSelecta Biosciences to Present at the SVB Leerink 10th Annual Global Healthcare Conference
finance.yahoo.com - February 16 at 9:46 AM
Thinking about buying stock in Edesa Biotech, Phunware, Vertex Energy, electroCore, or Selecta Biosciences?Thinking about buying stock in Edesa Biotech, Phunware, Vertex Energy, electroCore, or Selecta Biosciences?
marketwatch.com - January 26 at 10:35 PM
Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene TherapySelecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy
finance.yahoo.com - January 6 at 10:06 AM
Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 ConferenceSelecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
finance.yahoo.com - January 4 at 8:17 AM
Selecta: ImmTOR Platforms Potential In KeySelecta: ImmTOR Platform's Potential In Key
seekingalpha.com - December 26 at 11:51 PM
Peter Traber Is The Chief Medical Officer of Selecta Biosciences, Inc. (NASDAQ:SELB) And Just Spent US$129k On SharesPeter Traber Is The Chief Medical Officer of Selecta Biosciences, Inc. (NASDAQ:SELB) And Just Spent US$129k On Shares
finance.yahoo.com - December 22 at 7:43 AM
Is SELB A Good Stock To Buy Now?Is SELB A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 6:08 PM
Selectas (SELB) Gene Therapy Gets Orphan Drug Tag From FDASelecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA
finance.yahoo.com - November 20 at 1:03 PM
Selectas gene therapy gets Orphan Drug tag for rare metabolic disorderSelecta's gene therapy gets Orphan Drug tag for rare metabolic disorder
seekingalpha.com - November 19 at 1:15 PM
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaAskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
finance.yahoo.com - November 19 at 8:15 AM
Party Time: Brokers Just Made Major Increases To Their Selecta Biosciences, Inc. (NASDAQ:SELB) Earnings ForecastsParty Time: Brokers Just Made Major Increases To Their Selecta Biosciences, Inc. (NASDAQ:SELB) Earnings Forecasts
finance.yahoo.com - November 9 at 10:52 AM
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call TranscriptSelecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 9:57 AM
Selecta Biosciences, Inc. (SELB) Q3 2020 Earnings Call TranscriptSelecta Biosciences, Inc. (SELB) Q3 2020 Earnings Call Transcript
fool.com - November 6 at 11:42 PM
Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate UpdatesSelecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
finance.yahoo.com - November 5 at 10:31 AM
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational HighlightsSelecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights
finance.yahoo.com - October 29 at 2:38 PM
Whats in Store for Selecta (SELB) This Earnings Season?What's in Store for Selecta (SELB) This Earnings Season?
finance.yahoo.com - October 27 at 1:25 PM
3 Top Healthcare Stocks Under $53 Top Healthcare Stocks Under $5
finance.yahoo.com - October 27 at 7:45 AM
Timothy Springer of Selecta Biosciences, Inc. (NASDAQ:SELB) Just Spent US$9.6m On SharesTimothy Springer of Selecta Biosciences, Inc. (NASDAQ:SELB) Just Spent US$9.6m On Shares
finance.yahoo.com - October 26 at 9:24 AM
Insider Weekends: Dr. Springer Significantly Increases His PurchasesInsider Weekends: Dr. Springer Significantly Increases His Purchases
seekingalpha.com - October 25 at 5:14 PM
Why Selecta Biosciences Stock Is Trading Higher TodayWhy Selecta Biosciences Stock Is Trading Higher Today
benzinga.com - October 21 at 10:23 PM
Selecta Bio/Asklepios gene therapy nabs Rare Pediatric Disease tag for inherited metabolic disorderSelecta Bio/Asklepios' gene therapy nabs Rare Pediatric Disease tag for inherited metabolic disorder
seekingalpha.com - October 20 at 3:03 PM
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic AcidemiaSelecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia
finance.yahoo.com - October 20 at 9:52 AM
Selecta Biosciences IncSelecta Biosciences Inc
bloomberg.com - October 15 at 6:38 PM
Selecta Bio inks research pact with IGAN Bio for kidney disease drug candidateSelecta Bio inks research pact with IGAN Bio for kidney disease drug candidate
seekingalpha.com - October 8 at 7:12 PM
Why Horizon Therapeutics, Selecta Biosciences Are Moving In SympathyWhy Horizon Therapeutics, Selecta Biosciences Are Moving In Sympathy
msn.com - October 1 at 5:30 PM
Selecta Drops on TrialsSelecta Drops on Trials
baystreet.ca - October 1 at 12:30 PM
SELB Down But Not Out, PFE Takes 9.9% Stake In CStone, ZSAN Plunges, AMAG On The Block?SELB Down But Not Out, PFE Takes 9.9% Stake In CStone, ZSAN Plunges, AMAG On The Block?
nasdaq.com - October 1 at 7:29 AM
First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory GoutFirst Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout
finance.yahoo.com - September 23 at 7:54 AM
Ornithine-Transcarbamylase Deficiency Market In-deep Analysis And Healthcare Experts Review Report 2020-2026Ornithine-Transcarbamylase Deficiency Market In-deep Analysis And Healthcare Experts Review Report 2020-2026
marketwatch.com - September 4 at 5:16 PM
Selecta Biosciences enters into $35M financing facilitySelecta Biosciences enters into $35M financing facility
seekingalpha.com - September 1 at 12:58 PM
Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley BankSelecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank
finance.yahoo.com - September 1 at 12:58 PM
If You Had Bought Selecta Biosciences (NASDAQ:SELB) Shares Three Years Ago You Would Be Down 86%If You Had Bought Selecta Biosciences' (NASDAQ:SELB) Shares Three Years Ago You Would Be Down 86%
finance.yahoo.com - August 29 at 12:02 AM
If You Had Bought Selecta Biosciences' (NASDAQ:SELB) Shares Three Years Ago You Would Be Down 86%If You Had Bought Selecta Biosciences' (NASDAQ:SELB) Shares Three Years Ago You Would Be Down 86%
finance.yahoo.com - August 28 at 6:58 PM
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2020 Results - Earnings Call TranscriptSelecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 5:33 PM
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.